Published in Hum Gene Ther on February 10, 2002
Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid-based therapeutics. Adv Drug Deliv Rev (2008) 1.74
Gene delivery through cell culture substrate adsorbed DNA complexes. Biotechnol Bioeng (2005) 1.50
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci U S A (2005) 1.35
Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films. Biomacromolecules (2006) 1.34
Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther (2011) 1.07
Pharmaceuticals for Intra-arterial Therapy. Semin Intervent Radiol (2005) 1.06
Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol (2007) 1.03
Development of adenovirus immobilization strategies for in situ gene therapy. J Gene Med (2008) 1.01
Gene Delivery by Immobilization to Cell-Adhesive Substrates. MRS Bull (2005) 0.89
Gene delivery technologies for cardiac applications. Gene Ther (2012) 0.87
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics (2014) 0.87
The use of reactive polymer coatings to facilitate gene delivery from poly (epsilon-caprolactone) scaffolds. Biomaterials (2009) 0.85
Cardiovascular gene delivery: The good road is awaiting. Adv Drug Deliv Rev (2006) 0.85
Polyelectrolyte multilayers promote stent-mediated delivery of DNA to vascular tissue. Biomacromolecules (2013) 0.83
Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules (2007) 0.83
The effects of Runx2 immobilization on poly (epsilon-caprolactone) on osteoblast differentiation of bone marrow stromal cells in vitro. Biomaterials (2010) 0.83
Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction. Biomaterials (2013) 0.82
Local gene delivery via endovascular stents coated with dodecylated chitosan-plasmid DNA nanoparticles. Int J Nanomedicine (2010) 0.82
Digoxigenin modification of adenovirus to spatially control gene delivery from chitosan surfaces. J Control Release (2009) 0.81
Development of viral vectors for use in cardiovascular gene therapy. Viruses (2010) 0.81
Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. Angiol Open Access (2015) 0.77
Immobilization of FLAG-Tagged Recombinant Adeno-Associated Virus 2 onto Tissue Engineering Scaffolds for the Improvement of Transgene Delivery in Cell Transplants. PLoS One (2015) 0.75
Controlling the surface-mediated release of DNA using 'mixed multilayers'. Bioeng Transl Med (2016) 0.75
Drug- and Gene-eluting Stents for Preventing Coronary Restenosis. Chonnam Med J (2017) 0.75
Neoatherosclerosis and Late Thrombosis After Percutaneous Coronary Intervention: Translational Cardiology and Comparative Medicine from Bench to Bedside . Yale J Biol Med (2017) 0.75
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J (2006) 3.43
A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med (2008) 2.60
Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg (2003) 2.38
Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg (2005) 2.32
In-vivo dynamic deformation of the mitral valve anterior leaflet. Ann Thorac Surg (2006) 2.28
Factors associated with poorer prognosis for patients undergoing primary percutaneous coronary intervention during off-hours: biology or systems failure? JACC Cardiovasc Interv (2008) 2.22
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials (2005) 2.01
Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation (2004) 2.00
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Hypercholesterolemia suppresses inwardly rectifying K+ channels in aortic endothelium in vitro and in vivo. Circ Res (2006) 1.85
Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv (2008) 1.84
High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A (2008) 1.82
Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol (2007) 1.77
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
Cholesterol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. Ann Thorac Surg (2006) 1.63
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness. Ann Thorac Surg (2011) 1.46
Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation (2002) 1.45
Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv (2008) 1.44
Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol (2007) 1.40
The vulnerable artery: early and rapid deposition of lipid in coronary arteries is associated with subsequent development of thin-cap fibroatheromas. EuroIntervention (2016) 1.40
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA (2003) 1.36
Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg (2007) 1.36
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci U S A (2005) 1.35
Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis (2006) 1.34
The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine (2009) 1.32
A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J (2007) 1.30
Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol (2002) 1.30
The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol (2011) 1.30
Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol (2008) 1.21
A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater (2009) 1.21
Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A (2010) 1.19
The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Biomaterials (2011) 1.17
Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. FASEB J (2007) 1.14
Diagnosis of thin-cap fibroatheromas by a self-contained intravascular magnetic resonance imaging probe in ex vivo human aortas and in situ coronary arteries. J Am Coll Cardiol (2005) 1.11
A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment. Nanoscale Res Lett (2009) 1.10
Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation (2008) 1.10
Porcine models of coronary atherosclerosis and vulnerable plaque for imaging and interventional research. EuroIntervention (2009) 1.07
Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol (2003) 1.06
Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. Biomaterials (2012) 1.04
Blood flow reprograms lymphatic vessels to blood vessels. J Clin Invest (2012) 1.04
Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry. Circ Cardiovasc Qual Outcomes (2009) 1.04
Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol (2002) 1.04
Delivery and expression of pDNA embedded in collagen matrices. J Control Release (2004) 1.03
Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex. Am J Physiol Heart Circ Physiol (2008) 1.03
Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis (2002) 1.03
Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother (2006) 1.02
Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release (2010) 1.02
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J Control Release (2011) 1.01
Ethnic differences in the presentation, treatment strategy, and outcomes of percutaneous coronary intervention (a report from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol (2003) 1.00
Site specific gene delivery in the cardiovascular system. J Control Release (2005) 0.99
Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res (2007) 0.97
Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv (2011) 0.97
In vivo biomechanical assessment of triglycidylamine crosslinked pericardium. Biomaterials (2007) 0.96
Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression. Mol Ther (2006) 0.95
Electron-beam computerized tomography correlates with coronary angiogram in chronic kidney disease patients. Am J Nephrol (2007) 0.95
Triglycidylamine crosslinking of porcine aortic valve cusps or bovine pericardium results in improved biocompatibility, biomechanics, and calcification resistance: chemical and biological mechanisms. Am J Pathol (2005) 0.94
Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail (2013) 0.94
Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis (2013) 0.94
Immobilization of gene vectors on polyurethane surfaces using a monoclonal antibody for localized gene delivery. J Gene Med (2006) 0.94
Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis. Arterioscler Thromb Vasc Biol (2012) 0.94
Paclitaxel-loaded polymeric micelles based on poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) triblock copolymers: in vitro and in vivo evaluation. Nanomedicine (2011) 0.93
Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia. J Diabetes Res (2013) 0.93
Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation (2004) 0.93
A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs. Contraception (2006) 0.92
Endovascular microcoil gene delivery using immobilized anti-adenovirus antibody for vector tethering. Stroke (2002) 0.92
Serotonin transporter mechanisms and cardiac disease. Circulation (2006) 0.91
Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy. J Gene Med (2008) 0.91
Completeness of revascularization for multivessel coronary artery disease and its effect on one-year outcome: a report from the NHLBI Dynamic Registry. J Interv Cardiol (2007) 0.91
One-year clinical outcomes of protected and unprotected left main coronary artery stenting. Eur Heart J (2003) 0.90
Patient satisfaction is comparable to early discharge versus overnight observation after elective percutaneous coronary intervention. J Invasive Cardiol (2009) 0.89
Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate. Biomaterials (2006) 0.89
Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J (2003) 0.89
Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. FASEB J (2013) 0.89
Comparison of invasive and noninvasive assessment of aortic stenosis severity in the elderly. Circ Cardiovasc Interv (2012) 0.89
Hypercholesterolemia suppresses Kir channels in porcine bone marrow progenitor cells in vivo. Biochem Biophys Res Commun (2007) 0.88
Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J Nanomedicine (2009) 0.88
Local delivery of modified paclitaxel-loaded poly(epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J Pharm Sci (2009) 0.88
Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. J Clin Invest (2012) 0.88
Thymosin beta4 regulation, expression and function in aortic valve interstitial cells. J Heart Valve Dis (2002) 0.88
Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: implications for gene therapy of restenosis. Atherosclerosis (2013) 0.88
Site-specific gene therapy for cardiovascular disease. Curr Opin Drug Discov Devel (2010) 0.87
Atherosclerotic plaque development. Int J Biochem Cell Biol (2009) 0.87
Effect of gender on prognosis following percutaneous coronary intervention for stable angina pectoris and acute coronary syndromes. Am J Cardiol (2006) 0.86
Triglycidyl amine crosslinking combined with ethanol inhibits bioprosthetic heart valve calcification. Ann Thorac Surg (2011) 0.86
Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries. Circ Cardiovasc Interv (2011) 0.86
Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease. Am J Physiol Heart Circ Physiol (2010) 0.86